162 related articles for article (PubMed ID: 37665737)
1. Efficacy and safety of nintedanib and docetaxel in patients with previously treated lung non-squamous non-small cell lung cancer: a multicenter retrospective real-world analysis.
Ljubicic L; Janzic U; Unk M; Terglav AS; Mohorcic K; Seiwerth F; Bitar L; Badovinac S; Plestina S; Korsic M; Kukulj S; Samarzija M; Jakopovic M
Radiol Oncol; 2023 Sep; 57(3):397-404. PubMed ID: 37665737
[TBL] [Abstract][Full Text] [Related]
2. Real-World Efficacy of Nintedanib Plus Docetaxel After Progression on Immune Checkpoint Inhibitors: Results From the Ongoing, Non-interventional VARGADO Study.
Grohé C; Blau W; Gleiber W; Haas S; Hammerschmidt S; Krüger S; Müller-Huesmann H; Schulze M; Wehler T; Atz J; Kaiser R
Clin Oncol (R Coll Radiol); 2022 Jul; 34(7):459-468. PubMed ID: 35012901
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
Reck M; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Gann CN; Barrueco J; Gaschler-Markefski B; Novello S;
Lancet Oncol; 2014 Feb; 15(2):143-55. PubMed ID: 24411639
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma.
Riudavets M; Bosch-Barrera J; Cabezón-Gutiérrez L; Diz Taín P; Hernández A; Alonso M; Blanco R; Gálvez E; Insa A; Mielgo X; Morán T; Ponce S; Roa D; Sánchez JM; Majem M
Clin Transl Oncol; 2021 Dec; 23(12):2560-2567. PubMed ID: 34292495
[TBL] [Abstract][Full Text] [Related]
5. Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy.
Reck M; Syrigos K; Miliauskas S; Zöchbauer-Müller S; Fischer JR; Buchner H; Kitzing T; Kaiser R; Radonjic D; Kerr K
Lung Cancer; 2020 Oct; 148():159-165. PubMed ID: 32927350
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program.
Corral J; Majem M; Rodríguez-Abreu D; Carcereny E; Cortes ÁA; Llorente M; López Picazo JM; García Y; Domine M; López Criado MP
Clin Transl Oncol; 2019 Sep; 21(9):1270-1279. PubMed ID: 30771085
[TBL] [Abstract][Full Text] [Related]
7. Nintedanib plus docetaxel after progression on first-line immunochemotherapy in patients with lung adenocarcinoma: Cohort C of the non-interventional study, VARGADO.
Grohé C; Wehler T; Dechow T; Henschke S; Schuette W; Dittrich I; Hammerschmidt S; Müller-Huesmann H; Schumann C; Krüger S; Atz J; Kaiser R
Transl Lung Cancer Res; 2022 Oct; 11(10):2010-2021. PubMed ID: 36386456
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC: A multi center prospective study.
Jiang Q; Zhang NL; Ma DY; Tan BX; Hu X; Fang XD
Medicine (Baltimore); 2019 Jun; 98(26):e16065. PubMed ID: 31261514
[TBL] [Abstract][Full Text] [Related]
9. Real-world efficacy of docetaxel plus nintedanib after chemo-immunotherapy failure in advanced pulmonary adenocarcinoma.
Metzenmacher M; Rizzo F; Kambartel K; Panse J; Schaufler D; Scheffler M; Azeh I; Hoiczyk M; Turki AT; Atz J; Buchner H; Hoffmann C; C Christoph D
Future Oncol; 2021 Oct; 17(30):3965-3976. PubMed ID: 34287064
[TBL] [Abstract][Full Text] [Related]
10. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
Arrieta O; Barrón F; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Yamamoto Ramos M; Mota-Vega B; Carmona A; Peralta Álvarez MP; Bautista Y; Aldaco F; Gerson R; Rolfo C; Rosell R
JAMA Oncol; 2020 Jun; 6(6):856-864. PubMed ID: 32271354
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review.
Garon EB; Visseren-Grul C; Rizzo MT; Puri T; Chenji S; Reck M
Front Oncol; 2023; 13():1247879. PubMed ID: 37731641
[TBL] [Abstract][Full Text] [Related]
13. Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology.
Dhillon S
Target Oncol; 2015 Jun; 10(2):303-10. PubMed ID: 25894578
[TBL] [Abstract][Full Text] [Related]
14. Nintedanib plus docetaxel after progression on immune checkpoint inhibitor therapy: insights from VARGADO, a prospective study in patients with lung adenocarcinoma.
Grohé C; Gleiber W; Haas S; Losem C; Mueller-Huesmann H; Schulze M; Franke C; Basara N; Atz J; Kaiser R
Future Oncol; 2019 Aug; 15(23):2699-2706. PubMed ID: 31282758
[No Abstract] [Full Text] [Related]
15. Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02-15 study).
Auliac JB; Monnet I; Bizieux A; Greillier L; Geier M; Falchero L; Le Garff G; Lamy R; Guisier F; Ricordel C; Chouaid C; Vergnenegre A;
Lung Cancer; 2021 Nov; 161():122-127. PubMed ID: 34583220
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With
Huang Z; Yan H; Zeng L; Xu Q; Guo W; Lin S; Jiang W; Wang Z; Deng L; Qin H; Zhang X; Tong F; Zhang R; Liu Z; Zhang L; Dong X; Yang N; Zhang Y
JCO Precis Oncol; 2023 Mar; 7():e2200614. PubMed ID: 36952645
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis.
Li Y; Liang X; Li H; Chen X
Chin Med J (Engl); 2023 Sep; 136(18):2156-2165. PubMed ID: 37596898
[TBL] [Abstract][Full Text] [Related]
18. Could S-1-based non-platinum doublet chemotherapy be a new option as a second-line treatment for advanced non-small cell lung cancer patients? A multicenter retrospective study.
Wang X; Wang T; Chu Y; Liu J; Yi C; Yu X; Wang Y; Zheng T; Cao F; Qu L; Yu B; Liu H; Ding F; Wang S; Wang X; Hao J; Wang X
Front Oncol; 2023; 13():1089234. PubMed ID: 37007066
[TBL] [Abstract][Full Text] [Related]
19. Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer; GENESIS-SEFH drug evaluation report.
Espinosa Bosch M; Asensi Diez R; García Agudo S; Clopes Estela A
Farm Hosp; 2016 Jun; 40(4):316-27. PubMed ID: 27571499
[TBL] [Abstract][Full Text] [Related]
20. Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial.
Hanna NH; Kaiser R; Sullivan RN; Aren OR; Ahn MJ; Tiangco B; Voccia I; Pawel JV; Kovcin V; Agulnik J; Gaschler-Markefski B; Barrueco J; Sikken P; Schloss C; Kim JH;
Lung Cancer; 2016 Dec; 102():65-73. PubMed ID: 27987591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
